Relevant studies suggest that the mechanisms of multiple myeloma resistance to daratumumab are associated with immune escape [5], as relapsing patients show stable expression of unmutated CD38 on cancer cells, which preserves their ability to be targeted by daratumumab [6]. The gene discussed is CD38; the disease is plasma cell myeloma.